Multifaceted role of matrix metalloproteinases (MMPs)

Frontiers in Molecular Biosciences

Volumn 2, Issue MAY, 2015, Pages

  Singh, Divya ^a   Srivastava, Sanjeev K ^b   Chaudhuri, Tapas K ^b   Upadhyay, Ghanshyam ^a  

^a CITY COLLEGE OF NEW YORK   (United States)

^b UNIVERSITY OF NORTH BENGAL   (India)

Author keywords

Glaucoma; Japanese encephalitis; MMP2; MMP9; Neurodegenerative disorders

Indexed keywords

EID: 84983137706     PISSN: None     EISSN: 2296889X     Source Type: Journal    
DOI: 10.3389/fmolb.2015.00019     Document Type: Review

References (56)

1. Calkins, D. J., and Horner, P. J. (2012). The cell and molecular biology of glaucoma: axonopathy and the brain. Invest. Ophthalmol. Vis. Sci. 53, 2482-2484. doi: 10.1167/iovs.12-9483i
2. Candelario-Jalil, E., Yang, Y., and Rosenberg, G. A. (2009). Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983-994. doi: 10.1016/j.neuroscience.2008.06.025
3. Choi, D. H., Kim, E. M., Son, H. J., Joh, T. H., Kim, Y. S., Kim, D., et al. (2008). A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J. Neurochem. 106, 405-415. doi: 10.1111/j.1471-4159.2008.05399.x
4. Choi, D. H., Kim, Y. J., Kim, Y. G., Joh, T. H., Beal, M. F., and Kim, Y. S. (2011). Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J. Biol. Chem. 286, 14168-14177. doi: 10.1074/jbc. M111.222430
5. Chung, Y. C., Kim, Y. S., Bok, E., Yune, T. Y., Maeng, S., and Jin, B. K. (2013). MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediat. Inflamm. 2013:370526. doi: 10.1155/2013/370526
6. De Groef, L., Van Hove, I., Dekeyster, E., Stalmans, I., and Moons, L. (2013). MMPs in the trabecular meshwork: promising targets for future glaucoma therapies? Invest Ophthalmol. Vis. Sci. 54, 7756-7763. doi: 10.1167/iovs.13-13088
7. Eisen, A. Z., Jeffrey, J. J., and Gross, J. (1968). Human skin collagenase. Isolation and mechanism of attack on the collagen molecule. Biochim. Biophys. Acta 151, 637-645. doi: 10.1016/0005-2744(68)90010-7
8. Ethell, I. M., and Ethell, D. W. (2007). Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J. Neurosci. Res. 85, 2813-2823. doi: 10.1002/jnr.21273
9. Forsyth, P. A., Wong, H., Laing, T. D., Rewcastle, N. B., Morris, D. G., Muzik, H., et al. (1999). Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer 79, 1828-1835. doi: 10.1038/sj.bjc.6690291
10. Fujioka, H., Dairyo, Y., Yasunaga, K., and Emoto, K. (2012). Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. Biochem. Res. Int. 2012:789083. doi: 10.1155/2012/789083
11. Gerometta, R., Kumar, S., Shah, S., Alvarez, L., Candia, O., and Danias, J. (2013). Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator. Invest. Ophthalmol. Vis. Sci. 54, 7903-7909. doi: 10.1167/iovs.13-12801
12. Gross, J., and Lapiere, C. M. (1962). Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. U.S.A. 48, 1014-1022. doi: 10.1073/pnas.48.6.1014
13. Guo, L., Moss, S. E., Alexander, R. A., Ali, R. R., Fitzke, F. W., and Cordeiro, M. F. (2005). Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest. Ophthalmol. Vis. Sci. 46, 175-182. doi: 10.1167/iovs.04-0832
14. Gupta, V., Singh, M. K., Garg, R. K., Pant, K. K., and Khattri, S. (2013). Evaluation of peripheral matrix metalloproteinase-1 in Parkinson's disease: a case-control study. Int. J. Neurosci. 124, 88-92. doi: 10.3109/00207454.2013.824438
15. Halfter, W., Willem, M., and Mayer, U. (2005). Basement membrane-dependent survival of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 46, 1000-1009. doi: 10.1167/iovs.04-1185
16. Halpern, D. L., and Grosskreutz, C. L. (2002). Glaucomatous optic neuropathy: mechanisms of disease. Ophthalmol. Clin. North. Am. 15, 61-68. doi: 10.1016/S0896-1549(01)00012-8
17. He, X., Zhang, L., Yao, X., Hu, J., Yu, L., Jia, H., et al. (2013). Association studies of MMP-9 in Parkinson's disease and amyotrophic lateral sclerosis. PLoS ONE 8:e73777. doi: 10.1371/journal.pone.0073777
18. Hu, J., Van Den Steen, P. E., Sang, Q. X., and Opdenakker, G. (2007). Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498. doi: 10.1038/nrd2308
19. Joo, S. H., Kwon, K. J., Kim, J. W., Hasan, M. R., Lee, H. J., Han, S. H., et al. (2010). Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells. Neurosci. Lett. 469, 352-356. doi: 10.1016/j.neulet.2009.12.026
20. Kalita, J., Kumar, S., Vijaykumar, K., Palit, G., and Misra, U. K. (2007). A study of CSF catecholamine and its metabolites in acute and convalescent period of encephalitis. J. Neurol. Sci. 252, 62-66. doi: 10.1016/j.jns.2006.10.010
21. Kim, E. M., and Hwang, O. (2011). Role of matrix metalloproteinase-3 in neurodegeneration. J. Neurochem. 116, 22-32. doi: 10.1111/j.1471-4159.2010.07082.x
22. Kim, Y. S., and Joh, T. H. (2006). Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med. 38, 333-347. doi: 10.1038/emm.2006.40
23. Kim, Y. S., Kim, S. S., Cho, J. J., Choi, D. H., Hwang, O., Shin, D. H., et al. (2005). Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25, 3701-3711. doi: 10.1523/JNEUROSCI.4346-04.2005
24. Kumar, S., Kalita, J., Saxena, V., Khan, M. Y., Khanna, V. K., Sharma, S., et al. (2009a). Some observations on the tropism of Japanese encephalitis virus in rat brain. Brain Res. 1268, 135-141. doi: 10.1016/j.brainres.2009.02.051
25. Kumar, S., Misra, U. K., Kalita, J., Khanna, V. K., and Khan, M. Y. (2009b). Imbalance in oxidant/antioxidant system in different brain regions of rat after the infection of Japanese encephalitis virus. Neurochem. Int. 55, 648-654. doi: 10.1016/j.neuint.2009.06.008
26. Kumar, S., Shah, S., Deutsch, E. R., Tang, H. M., and Danias, J. (2013a). Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes. Invest. Ophthalmol. Vis. Sci. 54, 1280-1287. doi: 10.1167/iovs.12-11223
27. Kumar, S., Shah, S., Tang, H. M., Smith, M., Borras, T., and Danias, J. (2013b). Tissue plasminogen activator in trabecular meshwork attenuates steroid induced outflow resistance in mice. PLoS ONE 8:e72447. doi: 10.1371/journal.pone.0072447
28. Laferla, F. M., Green, K. N., and Oddo, S. (2007). Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8, 499-509. doi: 10.1038/nrn2168
29. Leske, M. C., Heijl, A., Hyman, L., Bengtsson, B., Dong, L., and Yang, Z. (2007). Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 114, 1965-1972. doi: 10.1016/j.ophtha.2007.03.016
30. Lindvall, O., and Kokaia, Z. (2006). Stem cells for the treatment of neurological disorders. Nature 441, 1094-1096. doi: 10.1038/nature04960
31. Lorenzl, S., Albers, D. S., Narr, S., Chirichigno, J., and Beal, M. F. (2002). Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp. Neurol. 178, 13-20. doi: 10.1006/exnr.2002.8019
32. Lorenzl, S., Albers, D. S., Relkin, N., Ngyuen, T., Hilgenberg, S. L., Chirichigno, J., et al. (2003). Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem. Int. 43, 191-196. doi: 10.1016/S0197-0186(03)00004-4
33. Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., and Love, S. (2008). Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 18, 240-252. doi: 10.1111/j.1750-3639.2008.00132.x
34. Misra, U. K., Kumar, S., Kalita, J., Ahmad, A., Khanna, V. K., Khan, M. Y., et al. (2009). A study of motor activity and catecholamine levels in different brain regions following Japanese encephalitis virus infection in rats. Brain Res. 1292, 136-147. doi: 10.1016/j.brainres.2009.07.025
35. Pagenstecher, A., Stalder, A. K., Kincaid, C. L., Shapiro, S. D., and Campbell, I. L. (1998). Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152, 729-741
36. Quigley, H. A. (1999). Neuronal death in glaucoma. Prog. Retin. Eye Res. 18, 39-57. doi: 10.1016/S1350-9462(98)00014-7
37. Rosenberg, G. A. (2009). Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 8, 205-216. doi: 10.1016/S1474-4422(09)70016-X
38. Santos, A. R., Corredor, R. G., Obeso, B. A., Trakhtenberg, E. F., Wang, Y., Ponmattam, J., et al. (2012). beta1 integrin-focal adhesion kinase (FAK) signaling modulates retinal ganglion cell (RGC) survival. PLoS ONE 7:e48332. doi: 10.1371/journal.pone.0048332
39. Selkoe, D. J. (2008). Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb. Clin. Neurol. 89, 245-260. doi: 10.1016/S0072-9752(07)01223-7
40. Shin, E. J., Kim, E. M., Lee, J. A., Rhim, H., and Hwang, O. (2012). Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopaminergic cells: relevance to Parkinson's disease. Neurochem. Int. 60, 249-256. doi: 10.1016/j.neuint.2012.01.001
41. Shukla, V., Kumar Shakya, A., Dhole, T. N., and Misra, U. K. (2012). Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus. Neuroimmunomodulation 19, 241-254. doi: 10.1159/000335182
42. Shukla, V., Shakya, A. K., Dhole, T. N., and Misra, U. K. (2013). Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of children with Japanese encephalitis virus infection. Arch. Virol. 158, 2561-2575. doi: 10.1007/s00705-013-1783-7
43. Tatton, W. G., Chalmers-Redman, R. M., and Tatton, N. A. (2001). Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy. Eur. J. Ophthalmol. 11(Suppl. 2), S12-S22
44. Tung, W. H., Tsai, H. W., Lee, I. T., Hsieh, H. L., Chen, W. J., Chen, Y. L., et al. (2010). Japanese encephalitis virus induces matrix metalloproteinase-9 in rat brain astrocytes via NF-kappaB signalling dependent on MAPKs and reactive oxygen species. Br. J. Pharmacol. 161, 1566-1583. doi: 10.1111/j.1476-5381.2010.00982.x
45. Ulrich, R., Gerhauser, I., Seeliger, F., Baumgartner, W., and Alldinger, S. (2005). Matrix metalloproteinases and their inhibitors in the developing mouse brain and spinal cord: a reverse transcription quantitative polymerase chain reaction study. Dev. Neurosci. 27, 408-418. doi: 10.1159/000088455
46. Upadhyay, G., Shankar, S., and Srivastava, R. K. (2014). Stem cells in neurological disorders: emerging therapy with stunning hopes. Mol. Neurobiol. doi: 10.1007/s12035-014-8883-6. [Epub ahead of print]
47. van Den Steen, P. E., Dubois, B., Nelissen, I., Rudd, P. M., Dwek, R. A., and Opdenakker, G. (2002). Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375-536. doi: 10.1080/10409230290771546
48. Van Hove, I., Lemmens, K., Van De Velde, S., Verslegers, M., and Moons, L. (2012a). Matrix metalloproteinase-3 in the central nervous system: a look on the bright side. J. Neurochem. 123, 203-216. doi: 10.1111/j.1471-4159.2012.07900.x
49. Van Hove, I., Verslegers, M., Buyens, T., Delorme, N., Lemmens, K., Stroobants, S., et al. (2012b). An aberrant cerebellar development in mice lacking matrix metalloproteinase-3. Mol. Neurobiol. 45, 17-29. doi: 10.1007/s12035-011-8215-z
50. Walsh, D. M., Minogue, A. M., Sala Frigerio, C., Fadeeva, J. V., Wasco, W., and Selkoe, D. J. (2007). The APP family of proteins: similarities and differences. Biochem. Soc. Trans. 35, 416-420. doi: 10.1042/BST0350416
51. Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., et al. (2006). Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 24566-24574. doi: 10.1074/jbc. M602440200
52. Yang, C. M., Lin, C. C., Lee, I. T., Lin, Y. H., Chen, W. J., Jou, M. J., et al. (2012). Japanese encephalitis virus induces matrix metalloproteinase-9 expression via a ROS/c-Src/PDGFR/PI3K/Akt/MAPKs-dependent AP-1 pathway in rat brain astrocytes. J. Neuroinflammation 9:12. doi: 10.1186/1742-2094-9-12
53. Yin, K. J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., et al. (2006). Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 26, 10939-10948. doi: 10.1523/JNEUROSCI.2085-06.2006
54. Yong, V. W., Power, C., Forsyth, P., and Edwards, D. R. (2001). Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2, 502-511. doi: 10.1038/35081571
55. Yong, V. W., Zabad, R. K., Agrawal, S., Goncalves Dasilva, A., and Metz, L. M. (2007). Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J. Neurol. Sci. 259, 79-84. doi: 10.1016/j.jns.2006.11.021
56. Yong, V. W. (2005). Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6, 931-944. doi: 10.1038/nrn1807